

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: VON DER KAMMER <i>et al.</i> Appl. No.: <i>To be assigned</i> (U.S. Nat'l Phase of PCT/EP2004/052684) I.A. Filing Date: October 28, 2004 For: Diagnostic and Therapeutic Use of the Human DAX-1 Gene and Protein for Neurodegenerative Diseases	Confirmation No.: <i>To be assigned</i> Art Unit: <i>To be assigned</i> Examiner: <i>To be assigned</i> Atty. Docket: 2335.0160000/SRL/KPQ
---	---

Preliminary Amendment Under 37 C.F.R. § 1.115

Mail Stop PCT

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.